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Abstract
“Parkinson’s Disease (PD) is a neurodegenerative disorder affecting approximately 1% of elderly
Americans that results from progressive loss of dopaminergic neurons. Common motor symptoms of PD
include resting tremor, rigidity, bradykinesia or akinesia and postural instability” (Zesiewicz et al., 2009).
“Almost all patients with PD have non-motor and neuropsychiatric features, including sleep
disturbances, compulsive and impulsive behaviors, autonomic dysfunction and psychosis” (Fernandez,
2012). In the years to come, as the average age increases the amount of PD patients will also increase
due to the late onset of most PD cases. As the amount of PD cases caused by environmental factors
decreases, the amount of genetic PD research may increase significantly. There are several different
gene mutations that are believed to cause a form of inherited PD. “Mutations in leucine-rich repeat
kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease” (Li et al., 2009). In this
study we evaluated the appropriateness of the FVB/N-Tg(LRRK2*R1441G)135Cjli/J as a mouse model
compared to the symptoms commonly seen in human PD LRRK2 patients and to those of the common
reserpine induced model of PD.
Introduction
Parkinson’s disease is the second most common neurodegenerative disease in humans
(Lichtenbery et al., 2011). It is a disease that causes degeneration of dopamine producing neurons in
the substantia nigra pars compacta and ventral tegmental areas of the brain (Lichtenbery, et al., 2011).
The subsequent behavioral deficits include hyperkinesia, resting tremors, bradyskinesia, postural
instability, and muscle rigidity. L-dopa is commonly used to treat PD but is not without severe side
effects (Kuoppamaki et al., 2007). L-dopa causes a nonselective increase in dopaminergic activity at all
five dopamine receptors, and will cause severe side effects after several years of use. The side effects
include uncontrollable movements similar to that of Huntington’s disease and severely debilitating
hallucinations.
Parkinson’s disease can be found sporadically in the population, usually caused by
environmental, industrial or drug toxicity. The reserpine form of PD commonly used in mice is supposed
to model this form of sporadic PD. Reserpine acts as an “irreversible inhibitor of the vesicular
monoamine transporter 2 (VMAT-2)” (Fernandes et al., 2012). To test the usefulness of reserpine as a
mouse model of Parkinson's disease, three aspects of human Parkinson's disease were compared to the
mouse model. Behaviorally, the characteristics of human Parkinson's disease that were examined were
gait patterns, motor activation, and posture which were then compared to the animal model induced by
reserpine. Pharmacologically, carbidopa and L-dopa was administered to determine recovery from
symptoms. Anatomically, a tyrosine hydroxylase staining assay was performed on 40 µm sections to
determine loss of dopaminergic neurons. Data was collected on the behavior, pharmacology, and
anatomical aspects of this model to determine if reserpine does indeed induce a valid model of human
PD.
The genetic mutation in the LRRK2 gene is the most common form of familial Parkinson’s
disease and is modeled by the FVB/N-Tg(LRRK2*R1441G)135Cjli/J (LRRK2*R1441G) strain of laboratory
mice. “A mutation in the leucine-rich repeat kinase 2 (LRRK2) is the most common genetic cause of
Parkinson’s disease” (Yanping et al., 2009). To test the usefulness of this genetic model of PD, the three
factors discussed above were also examined here with the exception that the open-field was added to
the behavior testing to measure overall activity levels. The pharmacological and anatomical factors
were examined identically to the reserpine model.
This research not only examines two separate models of PD but also a tyrosine hydroxylase
assay to determine the anatomical deficits of these models. In previous research, there was no

comprehensive tyrosine hydroxylase assay available for use. To determine proper pathology and
dopamine depletion in the brain when modeling PD in animals, an anti-tyrosine hydroxylase stain should
be used. Using this type of stain allows for analysis of the affected areas and accurate pathology
diagnosis. To stain tyrosine hydroxylase positive neurons located in the substantia nigra pars compacta,
40 µm sagittal sections of both control and experimental reserpine brains were stained with an
immunohistochemical assay using a rabbit polyclonal anti-tyrosine hydroxylase antibody. Initially, the
assay described was modeled after Varcin and colleagues (2011). This research was extremely helpful,
but most steps were not fully described or were unnecessary. This required the development of a new
protocol. The full protocol was developed and validated using materials obtained from several different
sources (e.g., Varcin et al., 2011), Vector Laboratories Inc. and EMD Millipore Company.
Materials and Methods
Subjects
Thirty-four male C57BL/6J mice were bred at Winona State University from breeders purchased
from the Jackson Laboratory (Bar Harbor, ME). Mice were coded so that the experimenter was unaware
of their treatment condition (reserpine or placebo-control).
Seventeen (eight male and nine female) LRRK2*R1441G mice and 17 (seven male and ten
female) control mice were bred at Winona State University from breeders purchased from Jackson
Laboratory (Bar Harbor, ME). The subjects were allowed to age to 12 months without any type of
testing. Mice were coded so that the experimenter was unaware of their genetic condition (carrier or
non-carrier control). Eight (five male and three female) LRRK2*R1441G mice and eight (five male and
three female) control mice were allowed to age until the end of their natural lifespan or the
development of Parkinsonism.
Animals were housed in groups of four to eight animals and maintained on a reverse 12/12 hour
light/dark cycle in a temperature and humidity controlled vivarium, with continual access to food and
water. In the reserpine model, behavioral testing occurred 24 to 48 hours after the reserpine injection
or 30 minutes after the L-Dopa injection. All subjects were tested between six and eight weeks from
birth. In the LRRK2*R1441G model initial testing began at 12 months of age. All procedures followed
NIH guidelines for the care and use of laboratory animals, and were approved by the Winona State
University Animal Care and Use Committee.
Behavioral Testing
There were four separate behavioral tests that were used to measure motor and behavioral
activity in the LRRK2*R1441G mice. The first three behavior tests were also used in the reserpine
condition but the fourth test was only implemented for the LRRK2*R1441G. All behavior tests were
conducted during the dark phase of the light/dark cycle. The first three behavior tests were conducted
24 hours before the fourth behavior test. The first test was used to examine the posture of each
subject. A digital photograph was taken of each subject and the subject’s posture was rated as
“Abnormal” or “Normal”. The second test was used to measure the motor activation of the subject.
This test used a bar test similar to the one described by Tsung-Hsun et al. (2011) which measured the
amount of time it took for the subject to remove both front paws from the suspended bar. The third
test was used to measure the common shuffling gait that is seen in PD patients. Each subject had their
paws placed in a water soluble die and allowed to walk over a sheet of white paper (7.5 cm x 90 cm).
The subjects were allowed two minutes to walk the entire length of paper and the time it took to
complete was recorded. The distances between each paw were measured. Walking patterns were

examined to determine if the subjects maintained a normal walking pattern of the stereotypic shuffling
gait seen in PD patients. Only for the LRRK2*R1441G, 24 hours after the shuffling gait test was
concluded, the subjects were recorded with a digital video recorded and allowed to freely roam in an
open-field apparatus (43.2 cm x 43.2 cm) for five minutes. The open-field was conducted in the light
and several different variables were measured including amount of movement, rearing, quadrant
crossings, and if a resting tremor was observed.
Pharmacological Testing
The two most widely used drugs to treat PD in humans were tested for effectiveness in the
subjects to further validate each model. Levodopa (L-dopa) is the most common treatment for relieving
the symptoms of PD. Carbidopa must be used concurrently with L-dopa to prevent conversion into
dopamine prematurely by the peripheral nervous system before L-dopa passes through the blood-brainbarrier. Fifty minutes before behavioral testing, carbidopa was injected i.p. at 12.5 mg/kg and 30
minutes before behavioral testing, L-dopa was injected i.p. at 50 mg/kg. If the symptoms of PD were
reduced when examining the behavior, then this result was considered to be pharmacologic evidence in
support of the validation of the PD model.
Anatomical Testing
Immunohistochemical
After the completion of all motor and behavior tests, the subjects were sacrificed and each brain
was removed. For the LRRK2*R1441G mice, samples of the tail, ear and blood was also taken. The
brains were fixed in formalin for a minimum of 14 days and thin-sectioned at 40 µm. The sections were
then stained using a ployclonal anti-tyrosine hydroxylase stain obtained from Vector Laboratories Inc.
and EMD Millipore Company. This stained was used to determine a distinct pathology of PD, loss of
dopaminergic neurons within the substantia nigra pars compacta, by showing the amount of tyrosine
hydroxylase positive neurons within the area. The full immunohistochemical staining process is
described below.
Materials
All necessary materials were obtained from Vector Laboratories, Inc., EMD Millipore Company and
Invitrogen of Life Technologies. The only material obtained from EMD Millipore Company was the
rabbit polyclonal anti-tyrosine hydroxylase antibody (Cat. # AB152). Critical materials were also received
from Vector Laboratories, Inc. which included the Vectastain® ABC Kit (PK-4001) and DAB Substrate Kit
(SK-4100). Normal goat serum and Tris-saline was obtained from Invitrogen.
Day One
The staining assay began with three washes in Tris-saline for five minutes each. Note: Tris-saline
concentration was held constant throughout protocol at 0.01 M TrisHCl at a pH of 7.4. A permeabilizing
treatment was then applied to the slides. Slides were incubated at 37oC in 0.1% Trypsin for 60 minutes.
The slides were then washed twice, five minutes each, in Tris-saline. The slides were quenched in
endogenous peroxidase for 30 minutes in 3% H2O2. Once again, the slides were washed in Tris-saline
two times at five minutes each. Next, a normal goat serum, diluted 20% in Tris-saline, was used for 45
minutes to block non-specific binding. Approximately, for the next 14 hours (exact time was 13 hours
and 56 minutes), the tissues were incubated in the rabbit polyclonal anti-tyrosine hydroxylase antibody
at room temperature. The rabbit polyclonal anti-tyrosine hydroxylase antibody was diluted 1:1000 in
Tris-saline along with 2% normal goat serum and 0.3% Triton X-100. Times varied depending on the

dilution of the rabbit polyclonal anti-tyrosine hydroxylase antibody and also the temperature at which
the tissues were incubated.
Day Two
Day two of the staining protocol began with two washes in Tris-Saline for five minutes each. For 60
minutes the tissues were incubated in the biotinylated secondary antibody at 37oC. The biotinylated
secondary antibody was diluted 1:200 in Tris-Saline and 2% normal goat serum. Slides were washed
twice in Tris-Saline for five minutes each. During the incubation in the biotinylated secondary antibody,
a horseradish peroxidase conjugate was mixed for 30 minutes before application. The horseradish
peroxidase conjugate was one mL Reagent A (Avidin DH) and one mL Reagent B (Biotinylated
Horseradish peroxidase H) provided in the Vectastain® ABC Kit diluted in 100 mL of 0.01% PBS. The
horseradish peroxidase conjugate was applied for 60 minutes. After the application of the horseradish
peroxidase conjugate, the slides were washed in Tris-saline twice for five minutes each. The tissues
were then rinsed in an acetate buffer solution for five minutes which consisted of 8.2 grams of sodium
acetate and 300 µL glacial acetic acid diluted in 1 L distilled water. The next step consisted of the
application of the 3,3’-diaminobenzidine which was mixed from the components from the DAB substrate
kit. The solution consisted of two drops of the buffer stock solution, four drops of the DAB stock
solution and two drops of a 3% hydrogen peroxide solution diluted and mixed well in 5 mL distilled
water. Average of two to three drops were applied to each section of tissue. There were two more
washes though Tris-saline at five minutes each and optimal staining was determined through light
microscopy. If proper staining is not obtained, the DAB substrate would need to be applied again along
with more washes through Tris-saline. If optimal staining is determined, then the tissues can be
dehydrated through alcohol. At five minutes each, the tissues were dehydrated through 70%, 95% and
100% alcohol. Finally, the slides were cleared with xylene for just over an hour. Slides were then
coverslipped and digitally photographed.
PCR

Specific to the LRRK2*R1441G subjects, genotyping via polymerase chain reaction (PCR) and gel
electrophoresis was completed to determine if the subjects did indeed have the correct mutation of the
LRRK2 gene using standard methods recommended by the distributor of this mouse model
(www.JAX.org).
Results
Tyrosine Hydroxylase Assay
The rabbit polyclonal anti-tyrosine hydroxylase antibody stained the proper structures of the
brain (see Figures 1 and 2). Figures 1 and 2 show the staining of the substantia nigra pars compacta.
Figure 3 shows that the cerebral cortex (negative control) appropriately was absent of staining. The
rabbit polyclonal anti-tyrosine hydroxylase antibody efficiently and effectively penetrated the soma of
the tyrosine hydroxylase positive neurons (see Figure 4). The rabbit polyclonal anti-tyrosine hydroxylase
antibody correctly stained axon and dendrite projections (see Figure 5). Figure 6 shows the staining of
all neurons within in substantia nigra pars compacta using a standard cresyl violet stain. Comparison of
the cresyl violet stained neurons to those stained for anti-tyrosine hydroxylase correctly reveals that
only a subset of neurons in the substantia nigra stain are dopaminergic.

Reserpine Model
Reserpine significantly altered the shuffling gait distance (cm) t(25)= 5.25323, p < .05. Subjects
in the control group had significantly longer gait distances than subjects in the reserpine only group.
Reserpine significantly altered the shuffling gait time (s) t(25)= -4.507621, p < .05. Subjects in the
reserpine only group had significantly longer times than subjects in the control group. Reserpine
significantly altered the bar time (s) t(25)= -2.641695, p < .05 (see Figure 8). Subjects in the reserpine
only group had significantly longer times than subjects in the control group.
Combined treatment with reserpine, carbidopa and L-dopa (RC(12.5)L(50)) significantly altered
the shuffling gait distance (cm) t(18)= 7.701276, p < .05 (see Figure 6). Subjects in the control group had
significantly longer gait distance than subjects in the RC(12.5)L(50) group. RC(12.5)L(50) significantly
altered the shuffling gait time (s) t(18)= -8.213235, p < .05. Subjects in the RC(12.5)L(50) group had
significantly longer times than subjects in the control group. RC(12.5)L(50) significantly altered the bar
time (s) t(18)= -31.01461, p < .05. Subjects in the RC(12.5)L(50) group had significantly longer times than
subjects in the control group.
RC(12.5)L(50) did not ameliorate the impairments in shuffling gait distance (cm) t(19)= 1.441261, p > .05. Subjects in the reserpine only group did not have significantly longer gait distances
than subjects in the RC(12.5)L(50) group. RC(12.5)L(50) also did not alter the shuffling gait time (s)
t(19)= 0.4508894, p > .05 (see Figure 7). Subjects in the RC(12.5)L(50) group did not have significantly
longer times than subjects in the reserpine only group. RC(12.5)L(50) significantly altered the bar time
(s) t(19)= 3.497898, p < .05. Subjects in the RC(12.5)L(50) group had significantly longer times than
subjects in the reserpine only group.
Reserpine significantly affected the posture χ2 = 21.950, p < .05 (see Figure 1) compared to the
control group. RC(12.5)L(50) significantly affected the posture χ2 = 25.898, p < .05 compared to the
control group. Reserpine did not significantly affect posture χ2 = 2.677, p < .05 compared to the
RC(12.5)L(50).
Reserpine did not alter the average color intensity of the polyclonal anti-tyrosine hydroxylase
stain t(17)= 0.1149269, p > .05 (see Figure 2). Subjects in the reserpine only group did not have
significantly less tyrosine hydroxylase positive neurons than subjects in the control group.

Figure 1. 40 µm sagittal section of the substantia nigra pars
compacta in a C57BL/6J mouse at 10x power.

Figure 2. 40 µm sagittal section of the substantia nigra pars
compacta in a C57BL/6J mouse at 10x power.

Figure 3. 40 µm sagittal section of the cerebral cortex in a
C57BL/6J mouse at 4x power.

Figure 4. 40 µm sagittal section of the substantia nigra pars
compacta in a C57BL/6J mouse at 40x power.

Figure 5. 40 µm sagittal section of the substantia nigra pars
compacta in a C57BL/6J mouse at 40x power.

Figure 6. 40 µm sagittal section of the substantia nigra pars
compacta in a C57BL/6J mouse with cresyl violet at 40x
power.
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Figure 6. Control vs. RC(12.5)L(50) gait distance.
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Figure 7. RC(12.5)L(50) vs. reserpine gait time.
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Figure 8. Control vs. reserpine bar time.
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Figure 9. Posture of C57BL/6J reserpine and C57BL/6J control mice.
LRRK2*R1441G Model
Currently, the part of the study that is examining the validity of the LRRK2*R1441G is still in
progress. Behavioral evaluations at 10 months, 12 months and 18 months have failed to detect any
behavioral indications of parkinsonism that are statistically different from controls. Because the study
design requires the continued maintenance of the subjects until symptoms develop we are continuing to
maintain the colony. The maximum lifespan of the laboratory mouse is 18 to 24 months. It is expected
that this portion of the study will end within the next six months.
Discussion
Tyrosine Hydroxylase Assay
This study has shown that the steps taken throughout the staining process are effective for
showing tyrosine positive neurons in the substantia nigra pars compacta. The rabbit polyclonal antityrosine hydroxylase antibody has been previously shown to be effective in doing so; not only in the
substantia nigra, but also other structures within the brain. Without a comprehensive assay to follow, it
is exceptionally difficult for independent researchers to do this process themselves. In the article
published by Varcin et al. (2011), the process of staining is extremely helpful but not fully complete. This
is similar to the protocols received from both EMD Millipore Company and Vector Laboratories Inc.
For example, as explain by Varcin and colleagues, the sections were incubated “with rabbit
polyclonal anti-TH antibody at room temperature overnight”. As described in the protocol obtained by
Millipore, the incubation times at room temperature range from two to eighteen hours. The protocol
described in Vector Laboratories describes incubating sections for 30 minutes at an unknown
temperature. Two protocols describe different thicknesses at which the tissue should be sectioned,
also. Varcin et al. sectioned at 50 µm and Millipore ranges from 15 to 30 µm. At different thicknesses
and temperatures, times of incubation may vary drastically. The information provided by all three
protocols ranges significantly, and because of this range, it is difficult for one to determine what may or
may not actually work. This study has found that at 40 µm, approximately 14 hours is a suitable time for
incubation in the primary antibody.
Another example of the range in information is the application of the DAB substrate, 3’3diaminobenzidine. Varcin et al., describes it as simply as “3’3-diaminobenzidine was applied until
staining was optimal as determined by light microscopy”. The protocol obtained from Millipore

described this step as incubating the tissue at room temperature for two to thirty minutes in 50 mg
diaminobenzidine per 100 mL PBS with 33 µL of 30% H2O2. The protocol that was received from the
company, Vector Laboratories, who provided the DAB substrate kit described the process that was
explained in the methods section. The difference between this study and the protocol is that the 3’3diaminobenzidine was applied through a droplet form and not incubation as describe by Vector
Laboratories. This study found that a two to three droplet average provides optimal staining at 40 µm.
If the tissues were incubated in the 3’3-diaminobenzidine for two to ten minutes, a likely possibility
would be that the stain would not have worked.
There are several key features that need to be examined when determining the suitable staining
of tyrosine hydroxylase positive neurons. These factors include which brain structures were stained,
neuronal penetration (soma, axon, dendrites), number of neurons stained compared to cresyl violet,
and artifact levels. The brain structures that were stained are critical to determine if the rabbit
polyclonal anti-tyrosine hydroxylase antibody actually stained tyrosine hydroxylase positive neurons. If
large areas of the cerebral cortex had been stained, then we would be forced to conclude that this
protocol does not work. Since areas like the cerebral cortex had not been stained though and areas like
the substantia nigra pars compacta and basal ganglia were stained; we can determine that the antibody
was selective to the areas that contain tyrosine hydroxylase. Accurate neuronal penetration is also key
to determining effective staining. As shown by Figure 4, the antibody was able to penetrate the soma,
effectively showing which neurons were tyrosine hydroxylase positive. Comparing this to Figure 6
(substantia nigra pars compacta stained with cresyl violet) it is quite clear that the number of cells
stained is quite different. If the antibody had stained the same amount of cells as the cresyl violet, the
antibody would not be effective in staining only those neurons that contain tyrosine hydroxylase.
Looking at Figure 4 also shows accurate neuronal penetration with the staining of axons and dendrites
within the substantia nigra pars compacta. Finally, artifact levels can make or break the decision to use
a protocol. If there are large of amounts of artifact as shown by Figure 1, then the dilution of the
primary antibody or even the amount of the DAB substrate may need to be examined. Even though
there was strong soma penetration shown in Figures 1, 2, and 4, the amount of artifact may lead to a
skewed analysis of how well the stain actually did to identify tyrosine hydroxylase positive neurons.
Overall, the rabbit polyclonal anti-tyrosine hydroxylase antibody works as a stain to determine tyrosine
hydroxylase positive neurons. This fact is nothing new, but we have shown that using this protocol, 40
µm tissue sections will have proper tyrosine hydroxylase positive neuron placement, strong penetration
of somas, and can be used to determine the pathology of an animal model of Parkinson’s disease.
Reserpine Model
The results of this study show that the use of reserpine as a model of Parkinson’s disease should
be reconsidered. While reserpine was found to produce gait disturbances (see Figures 3 and 6),
decreased motor activation (see Figure 5 and 8), and postural deficits (see Figure 9) similar to the human
disease, the anatomical characteristics do not match the human disease (see Figure 1, 2, and 4).
Specifically there was no evidence of cell loss in the substantia nigra.
Anatomically, reserpine is not useful because there were no significant changes between the
analysis of control and reserpine treated mouse brains. Specifically, there was not a significant loss of
dopaminergic neurons. Reserpine does not cause the death of neurons (see Figure 1, 2, and 4). It only
reduces the amount of dopamine available for neurotransmission. This is very different from human
Parkinson’s where symptoms begin to manifest when more than 50% of the dopaminergic neurons have
died. To be considered anatomically valid, we would expect to see a significant difference in the amount
of tyrosine hydroxylase positive neurons between the control and reserpine subjects.

These data clearly show that the reserpine model is not pharmacologically valid. Combined
treatment with Carbidopa and L-dopa in human Parkinsonism works on the neurotransmitter level
allowing more L-dopa to be available for conversion into dopamine. This allows the still living neurons
to flood the system with dopamine, compensating for the neuronal loss in Parkinson's disease. Testing
between the reserpine only and reserpine with carbidopa and L-dopa failed to produce significant
improvements in the severity of behavioral symptoms. This finding shows that a treatment that has
proven useful in humans with Parkinson’s disease does not reverse reserpine induced Parkinsonism.
This means that screening new drugs in this model could lead researchers to falsely reject drugs with
potential therapeutic properties.
When looking at reserpine as a full model of human Parkinson’s disease, we are forced to
conclude that it should not be used. Even though there are significant behavioral and postural
differences induced by reserpine, the use of reserpine as a model of Parkinson’s disease is not justified
in this study as it fails to produce the anatomical deficits associated with the disease and is not
reversible with the current antiparkinsonism drugs.
LRRK2*R1441G
The original developer of the LRRK2*R1441G mouse model reported that deficits appear by 10
months of age (Li et al, 2009). At the time of this report we had tested animals as old as 18 months and
have yet to find any symptoms of Parkinsonism. After starting the study we received a communication
from Jackson Labs (the distributor of the line) indicating that no one had been able to validate the
model. This communication caused us to look for possible factors. We believe we may have discovered
a possible reason. Recently it was reported that in an in vitro culture of cells from the LRRK2*R1441G
mouse the administration of a lipopolysaccharide (LPS) (an agent released by microglia during
neuroinflammation) triggers cell death in dopaminergic neurons from the substantia nigra (Gillardon et
al, 2012). This would mean that in persons with this gene a trigger capable of producing
neuroinflammation (e.g., a bacterial infection targeting the brain) could be the cause of their
parkinsonism. This would be an exciting breakthrough if confirmed in the complete model. For these
reasons, we have now divided our colony into two groups. The first group will continue on untreated
until they live out a natural lifespan or until they become symptomatic. The second group was given LPS
over a seven-day period to model the consequences of neuroinflammation. These animals are currently
being tracked along with the untreated group. Hopefully, within the next few months, we will be able
to say whether or not the disease will present without the use of LPS and whether or not the LPS
actually works to induce the disease.
We are grateful for the opportunity to complete this project and wish to thank the selection
committee for the award. This project would not have been possible without the financial support
provided by this grant. This opportunity was vital to our career development as the experience allowed
us to demonstrate our knowledge of the field and research abilities to prospective graduate schools.
Both of us were admitted to doctoral programs and we will begin our graduate studies in the fall of
2013.
Presentations Based on this Work: Portions of this work was presented at the 2012 annual meeting of
the annual Midbrains Undergraudate Neuroscience Conference of the Midwest.
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